摘要
讨论加强上市后药品安全性监测的重要性和必要性 ,介绍一些国家在药品上市后安全性监测方面的做法和经验 ,分析我国在药品上市后安全性监测工作的现状和不足 ,对我国今后开展药品上市后安全性监测提出一些初步建议。
The importance and necessity to strengthen the post-marketing surveillance of drug safety were briefly discussed and the practices and experience in this area of some foreign countries were introduced.The present situation,deficiency,and some preliminary suggestions in post-marketing surveillance of our country were also mentioned.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2001年第6期401-404,共4页
Chinese Journal of New Drugs